Assembly Biosciences Files 8-K
Ticker: ASMB · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1426800
| Field | Detail |
|---|---|
| Company | Assembly Biosciences, INC. (ASMB) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Assembly Bio filed an 8-K, but it's light on details.
AI Summary
Assembly Biosciences, Inc. filed an 8-K on September 23, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial figures or details about the nature of the "Other Events" beyond its classification.
Why It Matters
This 8-K filing indicates that Assembly Biosciences has made a regulatory submission, but it lacks specific details for investors to assess its immediate impact.
Risk Assessment
Risk Level: low — The filing is a standard procedural report without new material financial information or significant operational changes disclosed.
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific "Other Events" are being reported by Assembly Biosciences, Inc. in this 8-K filing?
The filing does not specify the nature of the "Other Events" beyond their classification.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 23, 2024.
In which state is Assembly Biosciences, Inc. incorporated?
Assembly Biosciences, Inc. is incorporated in Delaware.
What is the address of Assembly Biosciences, Inc.'s principal executive offices?
The address is Two Tower Place, 7th Floor, South San Francisco, California 94080.
Does this 8-K filing provide any new financial statements or exhibits?
The filing indicates "Financial Statements and Exhibits" are included, but the content of these is not detailed in the provided text.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-23 08:05:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Marke
Filing Documents
- asmb-20240923.htm (8-K) — 44KB
- asmb-ex99_1.htm (EX-99.1) — 36KB
- 0000950170-24-108629.txt ( ) — 205KB
- asmb-20240923.xsd (EX-101.SCH) — 30KB
- asmb-20240923_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 23, 2024, Assembly Biosciences, Inc. (the "Company") issued a press release announcing interim results from the Phase 1a portion of it ongoing Phase 1a/b clinical study evaluating ABI-5366, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate for recurrent genital herpes. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release dated September 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: September 23, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 2